Maryvonne Hiance is Vice-President of the Board and Strategic Director of OSE Immunotherapeutics, a biotech company developing activating or regulating immunotherapies in immuno-oncology, autoimmune diseases and transplantation, and is also Vice-President of the Atlanpôle Biothérapies (Nantes) cluster.
Maryvonne Hiance said: “I am delighted to be elected president of France Biotech and I wish to thank the board for their trust and support. I also wish to pay tribute to Pierre-Olivier Goineau for his commitment and all the work done during the past two years. I will strive both to carry on the relevant and effective initiatives that he developed and to implement new work areas aiming to bolster the development of this strategic French biotech sector, made up by close to 500 companies with great potential and features.
I am taking up the torch and undertake to work so that our business people benefit from the most favorable conditions for the development of their activities. I particularly want to work to remove the financial, tax, administrative and regulatory barriers so that these companies become major international players. I will be unveiling my roadmap in early September after the summer break. The roadmap will revolve around current and future issues for biotech companies, whether they are human, philosophical or economic, and will seek to strengthen the ties between the key players in our sector from the regional to the European level., in order to become a global force and deliver the therapeutic innovations of tomorrow.”
Maryvonne Hiance is a biotech entrepreneur and pioneer and has always been passionate about applied research and adding value to research findings (Atlanpôle). She took part in identifying the Nantes health cluster, in launching the New Market and has been involved in creating seed funds for innovative start-ups.
Maryvonne Hiance trained as an engineer specializing in nuclear power (Ecole Polytechnique and nuclear engineering) and began her career spending 14 years in nuclear medicine and then joined Framatome and its subsidiaries as an engineer in neutron studies. She has then managed various biotech innovation companies for over two decades: SangStat Atlantic, a company bought out by Genzyme in 2003 for its portfolio of immunosuppression and transplant products, DrugAbuse Sciences and TcLand. She has been a member of France’s Strategic Innovation Council and an advisor to the Minister for SME and industry.
In 2008, Maryvonne Hiance co-founded and chaired Effimune, a Biotech company specialized in immune regulation with clinical autoimmunity, transplant and immuno-oncology applications. In May 2016, she led Effimune’s merger with OSE Pharma in order to co-found OSE Immunotherapeutics.
The newly elected Board 20 members:
1. Maryvonne Hiance, Chairman, Co-Founder (OSE Immunotherapeutics)
2. Hervé Affagard, Chairman and CEO (Maat Pharma)
3. Sophie Baratte, Chairman and CEO (Cellnovo)
4. Hervé Balusson, Chairman and CEO (Groupe Olmix)
5. Pierre-Henri Benhamou MD., Chairman and CEO (DBV Technologies)
6. Christian Béchon, CEO (LFB)
7. Alain Clergeot, CEO (Theravecty)
8. David Caumartin, Chairman and CEO (Théraclion)
9. Frédéric Desdouits, EVP Head of Corporate Business Development, Acquisitions and Market Intelligence (Pierre Fabre)
10. Eric Falcand, Director, partnerships (Servier)
11. Michel Finance, CEO (Theradiag)
12. Jean-Marc Gandon, Chairman and CEO (BIOTRIAL)
13. Pierre-Olivier Goineau, Chairman (Neuronax)
14. Patrick Guérin, Chairman and CEO (OpenHealth)
15. Laurent Nguyen, Chairman and CEO (Sensorion)
16. Christine Placet, CEO (Horama)
17. Christian Policard, Associate Director, (Biotech Développement Conseils)
18. Alexandre Regniault, Associate Director, (Simmons & Simmons)
19. Miguel Sieler, CEO (Neovacs)
20. Daniel Vial, Consultant 3
About France Biotech
France Biotech brings together the main French life science companies and their expert partners. Its mission is to support the development of the French life sciences by advocating for a favorable regulatory and fiscal environment. In 2004, France Biotech successfully lobbied the French government to create a special fiscal status for innovative start-ups and continues to act as an advocate forthe French innovative sector. The organization is currently chaired by Maryvonne Hiance. France Biotech has over 150 members and its board of directors is composed of 20 entrepreneurs in the life sciences.
